Gastroesophageal reflux disease (GERD) is a chronic digestive disease that affects nearly 65 million people in the United States.1 It occurs when stomach acid or stomach contents flow back into your food pipe (esophagus). The backwash (reflux) irritates the lining of your esophagus and causes GERD.2 Frequent and troublesome symptoms may include one or more of the following: heartburn, regurgitation, sleep disruption, vocal impairment, and respiratory complications.
Most individuals with GERD are successfully treated with acid blocking medications such as proton pump inhibitors (PPI). However, nearly 30% of individuals on PPI medication continue to suffer from symptoms. If you or a loved one between the ages of 22 and 75 suffers from chronic reflux, take PPI medication, and continue to suffer from reflux symptoms, consider participating in the LESS GERD TRIAL.
The LESS GERD TRIAL will examine the effects of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System, a new minimally invasive approach to severe reflux treatment, on GERD outcomes, such as: esophageal pH (a)cid in the esophagus; GERD symptoms (heart)burn and regurgitation; and effect of GERD on overall quality of life. Visit www.lessgerd.com to learn more and take an online screening test.
Your doctor will review with you study specific requirements and then determine if you may be eligible for the study.
The LESS GERD TRIAL is taking place at:
Dignity Health St Joseph’s Hospital and Medical Center
500 W. Thomas Rd, Suite 500
Phoenix, AZ 85013
Ross Bremner, MD
Veta Clayton, RN, CCRC, CCRP
Contact the study coordinator listed above to discuss your interest in participating in this clinical trial.
The EndoStim system is not approved for sale in the US and is limited by US federal law to investigational use only. For more information, visit www.endostim.com.
1. National Institute of Diabetes and Digestive and Kidney Diseases, Definition and Facts for GER and GERD
2. Mayo Clinic, Diseases & Conditions